Pergi ke luar talian dengan aplikasi Player FM !
touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Manage episode 450026767 series 3389426
touchMDT for touchONCOLOGY
What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.
The multidisciplinary team:
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
102 episod
Manage episode 450026767 series 3389426
touchMDT for touchONCOLOGY
What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.
The multidisciplinary team:
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
102 episod
Semua episod
×1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38
1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15
1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20
1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19
1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58
1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.